AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05826119
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia induction was provided with propofol (2mg/kg), fentanyl (2mcg/kg). Intubation was performed after administration of 0.6 mg/kg rocuronium with an appropriate endotracheal tube. Anesthesia was maintained using AIR/O2 (50%/50%), 1 minimum alveolar concentration (MAC) sevoflurane, 0.1-0.25 mcg/kg/min remifentanil infusion. The target BIS value was kept between 40 and 50. Systolic blood pressure (SBP) \<90mmHg or \<20% of baseline was considered hypotension; remifentanil infusion was reduced. If no response was obtained, 5-10 mg of IV ephedrine was administered. HR \< 45 beats/min was evaluated as bradycardia; IV atropine 0.5 mg was planned The same volume of isotonic saline for the control group was administered as indicated in the magnesium group.
Trial: NCT05486728
Drug: SHJ002/Vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ophthalmic
Trial: NCT04180969
Drug: yohimbine + hydrocortisone
RxNorm normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: yohimbine 54mg + hydrocortisone 20mg oral
Trial: NCT04180969
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo stressor
Trial: NCT04742010
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * A single treatment 21 days before bariatric surgery with Zoledronic acid 5 mg or placebo (an interval of 5 to 180 days is accepted)~* Pharmaceutical form: Solution for infusion (100 ml normal saline containing 5 mg zoledronic acid or placebo)~* Administration: slow intravenous infusion with a duration of at least 15 minutes
Trial: NCT04742010
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as above
Trial: NCT04981704
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin Capsules
Trial: NCT05387603
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Will be given orally with a dose of 825/m2 twice daily, starting on day 1 of each of the 4 first treatment cycles, cycle length 3 weeks.
Trial: NCT05775874
Drug: AZD4547
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation dose: 80mg BID,po.
Trial: NCT06412861
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 mcg/kg fentanyl + 1 mg/kg propofol will be administered. Ramsay Sedation Score will be targeted to be \> 4. For this, if necessary, additional iv 0.5 mg/kg propofol will be administered.
Trial: NCT05163041
Drug: BT7480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a 60 minute IV infusion of BT7480 once weekly (i.e., on Days 1,8,15 and 22) during a 28-day cycle
Trial: NCT01675986
Drug: Lactose
RxNorm normalized name: Lactose
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g
Trial: NCT05000346
Drug: Drug, inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution administered by inhalation
Trial: NCT06133101
Drug: Standard Soy Milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consumption of commercially available soy milk
Trial: NCT06133101
Drug: 2% Fat Cow's Milk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consumption of commercially available 2% cow's milk
Trial: NCT06759363
Drug: Calcium Butyrate
RxNorm normalized name: calcium butyrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg/day of calcium-butyrate
Trial: NCT04456439
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants who are not currently taking a corticosteroid will receive hydrocortisone, 0.5-1 milligram per kilogram (mg/kg), up to 50 mg IV, at least 30 minutes prior to the infusion of remestemcel-L.
Trial: NCT04754100
Drug: agenT-797
RxNorm normalized name: MISCELLANEOUS AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
Trial: NCT05086445
Drug: LY3502970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05086445
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05235854
Drug: Injection of corticosteroids (Diprostène®)
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diprostène® will be injected into the knee. This is a 1 ml syringe of Betamethasone 2 mg, suspension for injection in pre-filled syringe.
Trial: NCT04593160
Drug: Diclofenac potassium- acetaminophen combination
RxNorm normalized name: acetaminophen / diclofenac potassium Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative single dose of diclofenac potassium(50mg)- acetaminophen(1000mg) combination
Trial: NCT04593160
Drug: Diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Preoperative single dose of diclofenac potassium(50mg)
Trial: NCT04593160
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative single dose of placebo
Trial: NCT05780463
Drug: MP0420
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MP0420 is a multi-valent DARPin® molecule (designed ankyrin repeat protein), consisting of 5 DARPin® domains.
Trial: NCT05780463
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercially available 0.9% sodium chloride solution
Trial: NCT06622239
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for 6 weeks
Trial: NCT06441994
Drug: PSW-1025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSMA (prostate specific membrane antigen)-targeted alpha therapy drug labeled with Astatine (At-211)
Trial: NCT05881915
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: epinephrine infusion dose of 0.03 mcg/Kg/min. epinephrine (1mg/ 1mL ampoule) will be diluted to reach a final concentration of 10 mcg/ml.
Trial: NCT06590961
Drug: UBX-303061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UBX-303061 oral dosage
Trial: NCT00002136
Drug: Tecogalan sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05544916
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets/day, for 5 days
Trial: NCT05616728
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule
Trial: NCT06377410
Drug: Syrup Prospan
RxNorm normalized name: Irospan Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participant with stable COPD who received Syrup prospan for 1 month
Trial: NCT06212492
Drug: NMBAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early and systematic use of NMBAs
Trial: NCT05132920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 2 ml Placebo daily for days 1-7 and 1 x 2 ml Placebo daily for days 8-21
Trial: NCT06605118
Drug: Azithromycin Injection
RxNorm normalized name: azithromycin Injection
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500mg azithromycin in 250 mL of normal saline
Trial: NCT06605118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL of normal saline
Trial: NCT06605118
Drug: Standard of Care Preoperative antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard of care preoperative antibiotics (excluding azithromycin) prior to incision
Trial: NCT06654336
Drug: ELIGARD 22.5mg
RxNorm normalized name: Eligard 22.5mg Suspension for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADT in the form of ELIGARD 22.5 mg every 3 months for a total of 12 months.
Trial: NCT06370975
Drug: 3% hypertonic Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the patients received 3% HS at the rate of 4 mL/kg for 30 minutes. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100
Trial: NCT06370975
Drug: Ringer's lactated solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the patients received ringer's lactated solution at the rate of 20 ml/kg for 30 minute. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100
Trial: NCT06370975
Drug: 0.9% Normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the patients received 0.9% Ns at the rate of 20 ml/kg for 30 minute. the intervention period for the study ran for the first hour of treatment, and serial monitoring and lab tests were done during this period, measurement lactate levels will done at 0, 30, 60 mins and 24 hour, the ABG parameters were recorded 30 and 60 min after the completion of the calculated dose infused with fluids and serial monitoring of vital parameters was done at 0, 15, 30, and 60 mins. The lactate clearance was calculated as follows:~-hour lactate clearance (%) = (0-hour lactate - 1-hour lactate) / 0-hour lactate × 100
Trial: NCT06655870
Drug: mRNA-0184
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injection
Trial: NCT05006911
Drug: Pilocarpine, brimonidine, oxymetazoline, hyaluronic acid, bromfenac (PBOHB) compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To determine the safety and efficacy of a PBOHB compound in near vision of presbyopic patients.
Trial: NCT05533411
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT05032807
Drug: Standard formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabidiol 1000mg standard formulation, single dose, oral
Trial: NCT05032807
Drug: Novel formulation
RxNorm normalized name: Novel Influenza-H1N1-09, all formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabidiol 1000mg with lipid matrix, single dose, oral
Trial: NCT04989101
Drug: Nigella
RxNorm normalized name: NIGELLA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The candidate must take one capsule / day of nigella 5 for 21 days (1 bottle). Follow-up should be done weekly for 1 month.
Trial: NCT04970797
Drug: Xinglouchengqi decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the composition of Xinglouchengqi decoction: 9 g raw rhubarb, 9 g mirabilite, 6 g dananxing, 30 g quangualou decoction was uniformly prepared by the pharmacy department of our hospital. Decoction form was adopted, one dose per day, one dose of 200 mL decoction, and the decoction was taken in morning and evening twice and half an hour after meals. The observation period was 5 days: from 72 hours to 7 days after onset.
Trial: NCT05755997
Drug: 0.9 % NaCl
RxNorm normalized name: dextrose 10 %-0.9 % NaCl MISCELL LIQUID (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml 0.9% NaCl per day for 4 days every month for 1 year
Trial: NCT05191680
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match apalutamide
Trial: NCT05051007
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive 1 mcg/kg of fentanyl (the drug will be diluted to 10 mcg/mL)
Trial: NCT06670053
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clinical testosterone therapy~No research interventions will be used as a part of the study since the research is observational. Testosterone treatment will be prescribed and followed by participant's clinical physician.
Trial: NCT06405243
Drug: Myoinositol
RxNorm normalized name: mesoinositol hexanicotinate
DrugBank: Inositol nicotinate (DB08949)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Myoinositol decreases insulin resistance and consequently increased intracellular glucose uptake, restore the metabolic profile and induce ovulation in PCOS patients with infertility, in addition to its good safety profile
Trial: NCT04511039
Drug: Trifluridine and Tipiracil Hydrochloride
RxNorm normalized name: tipiracil / trifluridine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05634759
Drug: Azithromycin for Routine Community-wide MDA
RxNorm normalized name: azithromycin Powder for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral azithromycin, also known as the brand name Zithromax®, is a macrolide antibiotic and is used in the treatment of active trachoma. The recommended dosage for the treatment of trachoma is a single dose of 20mg/kg of body weight and is implemented by a Age-height based dosing strategy for the trachoma MDA campaigns. Oral azithromycin can be administrated in either tablet form or powder for oral suspension (POS). Zithromax® is donated by Pfizer Inc through the International Trachoma Initiative (ITI) to the South Sudan Federal Ministry of Health to use in community-wide MDA throughout South Sudan.
Trial: NCT05634759
Drug: Two Additional Rounds of Azithromycin for Children
RxNorm normalized name: azithromycin Powder for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An additional round of treatment will be given one week after the routine community-wide MDA, and a second additional round will be given two weeks later (3 weeks after the routine community-wide MDA).
Trial: NCT05634759
Drug: Azithromycin for Second Community-wide MDA
RxNorm normalized name: azithromycin Powder for Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A second community-wide MDA will be given 6 to 8 months after the routine community-wide MDA. The timing of the second MDA will depend on local conditions and logistical concerns.
Trial: NCT04958538
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methylprednisolone 2 mg/kg/day MTX (5-10 mg/day) was given on days 1, 3, and 8, and repeated weekly until aGVHD was less than grade II
Trial: NCT04176978
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patient in this group will receive Rosuvastatin 20mg daily.
Trial: NCT06558032
Drug: Harnal® OCAS 0.4 mg Prolonged Release Tablet (produced by Astellas Pharma Europe B.V., The Netherlands, imported by PT Combiphar, Indonesia)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of the test drug was given orally under fasting condition
Trial: NCT05398198
Drug: GSK3923868
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3923868 dose and administration as per study intervention.
Trial: NCT05398198
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching GSK3923868 will be administered.
Trial: NCT05726136
Drug: albumin 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After insufflation of carbon dioxide during an abdominal laparoscopic procedure, the first bolus of fluid is infused. Circulatory and volume effects are studied. If cardiac output increases a second bolus is infused and studied.
Trial: NCT05321979
Drug: MBA-P01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MBA-P01 will be injected into the Glabellar line.
Trial: NCT06049498
Drug: Mongolian Medicine ZhenBao Pills Placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mongolian Medicine ZhenBao Pills placebo, orally, 15 pills each time, twice a day.
Trial: NCT05311618
Drug: NGM438
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGM438 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
Trial: NCT05199129
Drug: HCP1904-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take once daily for 8 weeks orally
Trial: NCT05199129
Drug: RLD2001-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take once daily for 8 weeks orally
Trial: NCT04856371
Drug: CYH33
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive oral CYH33 once daily on Days 1-28 of each 28-day cycle.
Trial: NCT04866225
Drug: Oral [14C]PF-06865571
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral radiolabeled PF-06865571
Trial: NCT04866225
Drug: IV [14C]PF-06865571
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV radiolabeled PF-06865571
Trial: NCT05499312
Drug: HKIIM-KU formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive HKIIM-KU formula granules (16.9g twice daily) for 8 weeks.
Trial: NCT05499312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo granules (16.9g twice daily) for 8 weeks.
Trial: NCT06259747
Drug: Doxylamine and Pyridoxine
RxNorm normalized name: Doxylamine and pyridoxine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: traditional medical treatment for nausea and vomiting during pregnancy
Trial: NCT05479058
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally once daily
Trial: NCT05485064
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The investigator 1 use fentanyl to sedate patients coordinate with remimazolam
Trial: NCT05485064
Drug: placebo needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigator 1 use placebo needle to sedate patients coordinate with remimazolam
Trial: NCT06500247
Drug: Androgen Deprivation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study recruited a total of 43 subjects diagnosed with mCRPC at multiple centers from July 2024. Enrolled patients received treatment with Androgen Deprivation Therapy until disease progression or intolerable toxicity, with a maximum treatment duration of up to 2 years. Follow-up visits were conducted monthly after patient enrollment. The last follow-up was completed in March 2027.
Trial: NCT04880616
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules matching NBI-827104 for oral administration
Trial: NCT05591105
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At the end of surgery, they will continue receiving analgesia according the schedule.
Trial: NCT06373991
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous injection of cyclophosphamide.
Trial: NCT06304220
Drug: Cerazet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparation of the utilization of two distinct progestogens for pituitary suppression
Trial: NCT06320067
Drug: Androgen Deprivation Therapy (ADT)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-term, continuous treatment with ADT (bilateral orchidectomy, LHRH agonists or LHRH antagonists) if not previously surgically castrated. The choice of ADT is at the discretion of the investigator. This will be given as standard of care as per local guidelines.
Trial: NCT06320067
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone should also be administered 5mg daily using local pharmacy prescribing.
Trial: NCT06056752
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous cyclophosphamide on days -5\~-3, the infusion dose is adjusted according to the subject's condition
Trial: NCT04965688
Drug: Drug determined by treating oncologist based on recommendation from systems biology analysis.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will have a biopsy at the beginning of the trial. The biopsy will be sent for DNA sequencing through FoundationOne(clinical test) and RNA profiling at Fulgent(research test) for determination of activation of various oncogenic pathways and phenotypes. The results will be analyzed and a treatment recommendation will be made to the treating physician based on an algorithm.
Trial: NCT04431518
Drug: JULUCA 50Mg-25Mg Tablet
RxNorm normalized name: JULUCA 50mg-25mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of JULUCA will be taken daily for up to 14 days
Trial: NCT05866055
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension for oral administration.
Trial: NCT05535998
Drug: Targeted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The TKI therapy used in this study were lenvatinib (12 mg/d for bodyweight ⩾ 60 kg or 8 mg/d for bodyweight \<60 kg), sorafenib (400 mg twice a day) or apatinib (250-500 mg orally once daily). Administration of lenvatinib, apatinib or sorafenib was started on the first post-TACE day, and continually administered until disease progression developed or serious treatment-related toxicity occurred.